- Home
- PGRE vs NRIX Comparison
PGRE vs NRIX Comparison
Compare PGRE & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGRE
- NRIX
- Stock Information
- Founded
- PGRE 1978
- NRIX 2009
- Country
- PGRE United States
- NRIX United States
- Employees
- PGRE N/A
- NRIX N/A
- Industry
- PGRE Real Estate Investment Trusts
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- PGRE Real Estate
- NRIX Health Care
- Exchange
- PGRE Nasdaq
- NRIX Nasdaq
- Market Cap
- PGRE 991.9M
- NRIX 1.1B
- IPO Year
- PGRE 2014
- NRIX 2020
- Fundamental
- Price
- PGRE $4.25
- NRIX $10.24
- Analyst Decision
- PGRE Hold
- NRIX Strong Buy
- Analyst Count
- PGRE 3
- NRIX 18
- Target Price
- PGRE $4.33
- NRIX $30.39
- AVG Volume (30 Days)
- PGRE 2.9M
- NRIX 1.3M
- Earning Date
- PGRE 04-30-2025
- NRIX 04-08-2025
- Dividend Yield
- PGRE 0.82%
- NRIX N/A
- EPS Growth
- PGRE N/A
- NRIX N/A
- EPS
- PGRE N/A
- NRIX N/A
- Revenue
- PGRE $710,365,000.00
- NRIX $56,417,000.00
- Revenue This Year
- PGRE $2.60
- NRIX $12.84
- Revenue Next Year
- PGRE N/A
- NRIX N/A
- P/E Ratio
- PGRE N/A
- NRIX N/A
- Revenue Growth
- PGRE 50.61
- NRIX N/A
- 52 Week Low
- PGRE $3.75
- NRIX $8.18
- 52 Week High
- PGRE $5.47
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- PGRE 52.62
- NRIX 39.72
- Support Level
- PGRE $4.03
- NRIX $9.23
- Resistance Level
- PGRE $4.26
- NRIX $10.17
- Average True Range (ATR)
- PGRE 0.20
- NRIX 1.04
- MACD
- PGRE 0.02
- NRIX 0.15
- Stochastic Oscillator
- PGRE 72.46
- NRIX 53.51
About PGRE Paramount Group Inc.
Paramount Group Inc is a real estate investment trust engaged in owning, operating, managing, acquiring, and redeveloping high-quality, Class A office properties in select central business district (CBD) submarkets of New York City and San Francisco. The company operates in two geographical segments New York and San Francisco. Paramount Group derives nearly all of its revenue in the form of rental income from leasing its offices to tenants.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.